I agree Carson, but I think that is precisely what this study with TD2 is going to get us. I like how this study will start prior to the Phase 2B, because positive results will help build momentum, and possibly give us the credibility needed to pick up more funding. Actually on the TD2 website there is a case study of a company that used TD2's services and as a result received funding to further research their product.
It is stated on the TD2 website under the pre-clinical section, in the following manner:
August 21, 2011
Preclinical Case Study: Lead Identification and Optimization
The Challenge:
A client created a small-batch panel of novel histone deacetylase inhibitors. The client did not have its own laboratory and had no information on potency, formulation, or overall context of activity of any of the drug candidates.
The Solution:
On the client's behalf, TD2 designed and executed in vitro potency evaluation of the novel molecules in with the goal of identifing a context for drug activity. TD2 identified a lead compounds and further characterized the lead compound as a HDAC6 targeting inhibitor in addition to a mutational context conferring sensitivity. To facilitate further in vivo evaluation of the compound, TD2 provided a cost-effective solution for compound scale-up. Following scale-up, TD2 created a safe vehicle for the lead compound for in vivo testing. Using the selected and optimized lead drug candidate TD2 confirmed efficacy of the compound in two human tumor models confirming the hypothesized context identified earlier and showed synergistic activity with standard of care agents.
The Result:
Due to the diligent planning and execution of the studies by TD2, the client's compound received preclinical investor funding for further development of the compound.
